Advertisement

Topics

Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases

08:00 EDT 14 Mar 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co., LTD. ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...